Praxis Precision Medicine has submitted two New Drug Applications (NDAs) to the FDA for its lead neurological candidates—ulixacaltamide for essential tremor and relutrigine for marking a major pivot toward commercialisation in 2026.
The FDA has granted breakthrough therapy designation to ulixacaltamide and is signalling regulatory focus on the drug’s potential for patients with neurological disorders.
The company is preparing for its first commercial launches as the NDA is supported by positive phase III data.
Praxis Precision Medicine focuses on therapies for neurological conditions. With ulixacaltamide and relutrigine now under FDA review, the company is shifting from a pure R&D story toward commercial operation.
The NDAs and commercial preparations with the narrative, Praxis are building a portfolio of late-stage CNS assets. This shift for Praxis Precision Medicines toward becoming a commercial-stage company with potential first product launches.
Breakthrough therapy designation for ulixacaltamide can mean more attention, potentially shorter timelines but it does not guarantee approval on the market.
At the same time, the continued large annual loss and need to fund several pivotal programs to test the idea that the pipeline alone reduces financing and execution risk.
Two NDAs on file, plus additional pivotal data expected in 2026, give Praxis multiple potential opportunities across essential tremor and severe epileptic encephalopathies, which could broaden its impact on the market.
Investors may want to consider whether current expectations fully reflect the timing and uncertainty across all four programs. The focus is on ulixacaltamide and relutrigine, while also highlighting vormatrigine and elsunersen.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
